Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study

NCT07832123 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT07832123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07832123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
September 30, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma : oligodendroglioma or astrocytoma